No Data
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Shanxi Meijin Energy (000723.SZ) participates in the public recruitment of investors for the reorganization of Changjiang Pharmaceutical Group.
Shanxi Meijin Energy (000723.SZ) announced that the company and the SiChuan Capital Markets Relief and Development Securities Investment Fund Partnership...
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Changjiang Pharmaceutical Group (300391.SZ): Subsidiary Changjiang Star has been petitioned for reorganization by creditors.
On February 12, Glorious Hong Kong announced that Changjiang Pharmaceutical Group (300391.SZ) disclosed that its subsidiary Hubei Changjiang Star Pharmaceutical Co., Ltd. (hereinafter referred to as "Changjiang Star") received the acceptance notice for the case from the Intermediate People's Court of Shiyan City, Hubei Province, numbered (2025) E 03 Bankruptcy Application No. 9. The applicant, Wuhan Century Baima System Engineering Co., Ltd., applied to the Shiyan Intermediate Court for the bankruptcy reorganization of Changjiang Star on the grounds that Changjiang Star is unable to pay its due debts and is clearly lacking in repayment ability, but still possesses reorganization value and feasibility. The Shiyan Intermediate Court filed the case on February 11, 2025.
Changyao Holdings: 2024 Annual Results Forecast
Changjiang Pharmaceutical Group (300391.SZ) issued a profit warning, expecting an annual net loss between 0.5 billion yuan and 0.75 billion yuan.
Changjiang Pharmaceutical Group (300391.SZ) disclosed its performance forecast for 2024, estimating that the profit attributable to the shareholders of the listed company...
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) Surges 52% Yet Its Low P/S Is No Reason For Excitement
